Digital Supplement

Potentially preventable intensive care unit admissions in the United States, 2006 - 2015

Gary E. Weissman, MD, MSHP; Meeta Prasad Kerlin, MD, MSCE; Yihao Yuan, MS; Rachel Kohn, MD, MSCE; George L. Anesi, MD, MBE, MSCE; Peter W. Groeneveld, MD, MS; Rachel M. Werner, MD, PhD; Scott D. Halpern, MD, PhD

August 29, 2019

Administrative definitions

Each year of data in each database provided a different number of diagnostic codes. In order to standardize our definitions and minimize classification bias, we used only the first ten diagnostic codes even when more were available.

Intensive care unit stay

Definitions for an intensive care unit (ICU) admission are based on a prior validation study (1). A hospitalization was considered to be associated with ICU care if any of the following revenue center codes was found in the claims: 200, 201, 202, 203, 204, 207, 208, 209, 210, 211, 212, 213, 219. These revenue center codes also correspond in the MedPAR database to ICU indicator codes 0, 1, 2, 3, 4, 7, 8 and 9, and to coronary care indicator codes 0, 1, 2, 3, and 9. Notably, codes for intermediate care units were not considered in this analysis.

Ambulatory care sensitive conditions

Ambulatory care sensitivity conditions were identified based on the published definitions of Prevention Quality Indicators (PQIs) from the Agency for Health Research and Quality (2). Version 5.0 of the definition was used for all claims from 2006 through the third quarter of 2015. Version 6.0 was used in the fourth quarter of 2015 to account for the transition to ICD-10 codes. We used the standard published definitions in all cases except for PQI 13 which was retired in version 6.0 and so was excluded from our definition of version 5.0.

Life-limiting malignancy

Life-limiting malignancy was defined using the published set of ICD-9 codes (Supplemental Table 1) used in a previous study examining eligibility and enrollment in hospice services among cancer patients(3). Since no comparable definition exists for ICD-10 codes, we used the 2016 CMS General Equivalency File to generate a corresponding set of ICD-10-CM codes (Supplemental Table 2). A hospitalization was considered associated with a life-

limiting malignancy if any of the reported diagnostic codes were found in the tables below. The code used to generate the ICD-10-CM codes is available online: https://gist.github.com/gweissman/63a162b64969f56b33ce5f6e0c13f51c

Supplemental Table E1: Previously published ICD-9-CM codes associated with a life-limiting
malignancy.

ICD-9	
Code	Diagnosis
1500	Malignant neoplasm of cervical esophagus
1501	Malignant neoplasm of thoracic esophagus
1502	Malignant neoplasm of abdominal esophagus
1503	Malignant neoplasm of upper third of esophagus
1504	Malignant neoplasm of middle third of esophagus
1505	Malignant neoplasm of lower third of esophagus
1508	Malignant neoplasm of other specified part of esophagus
1509	Malignant neoplasm of esophagus, unspecified site
151	Malignant neoplasm of stomach
1510	Malignant neoplasm of cardia
1511	Malignant neoplasm of pylorus
1512	Malignant neoplasm of pyloric antrum
1513	Malignant neoplasm of fundus of stomach
1514	Malignant neoplasm of body of stomach
1515	Malignant neoplasm of lesser curvature of stomach, unspecified
1516	Malignant neoplasm of greater curvature of stomach, unspecified
1518	Malignant neoplasm of other specified sites of stomach
1519	Malignant neoplasm of stomach, unspecified site
155	Malignant neoplasm of liver and intrahepatic bile ducts
1550	Malignant neoplasm of liver, primary
1551	Malignant neoplasm of intrahepatic bile ducts
1552	Malignant neoplasm of liver, not specified as primary or secondary
1570	Malignant neoplasm of head of pancreas
1571	Malignant neoplasm of body of pancreas
1572	Malignant neoplasm of tail of pancreas
1573	Malignant neoplasm of pancreatic duct
1574	Malignant neoplasm of islets of langerhans
1578	Malignant neoplasm of other specified sites of pancreas
1579	Malignant neoplasm of pancreas, part unspecified
1580	Malignant neoplasm of retroperitoneum

1588	Malignant neoplasm of specified parts of peritoneum
1589	Malignant neoplasm of peritoneum, unspecified
159	Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
1590	Malignant neoplasm of intestinal tract, part unspecified
1591	Malignant neoplasm of spleen, not elsewhere classified
1598	Malignant neoplasm of other sites of digestive system and intra-abdominal organs
1599	Malignant neoplasm of ill-defined sites within the digestive organs and peritoneum
1620	Malignant neoplasm of trachea
1622	Malignant neoplasm of main bronchus
1623	Malignant neoplasm of upper lobe, bronchus or lung
1624	Malignant neoplasm of middle lobe, bronchus or lung
1625	Malignant neoplasm of lower lobe, bronchus or lung
1628	Malignant neoplasm of other parts of bronchus or lung
1629	Malignant neoplasm of bronchus and lung, unspecified
1630	Malignant neoplasm of parietal pleura
1631	Malignant neoplasm of visceral pleura
1638	Malignant neoplasm of other specified sites of pleura
1639	Malignant neoplasm of pleura, unspecified
1641	Malignant neoplasm of heart
1642	Malignant neoplasm of anterior mediastinum
1643	Malignant neoplasm of posterior mediastinum
1648	Malignant neoplasm of other parts of mediastinum
1649	Malignant neoplasm of mediastinum, part unspecified
1650	Malignant neoplasm of upper respiratory tract, part unspecified
1658	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs
1659	Malignant neoplasm of ill-defined sites within the respiratory system
191	Malignant neoplasm of brain
1910	Malignant neoplasm of cerebrum, except lobes and ventricles
1911	Malignant neoplasm of frontal lobe
1912	Malignant neoplasm of temporal lobe
1913	Malignant neoplasm of parietal lobe
1914	Malignant neoplasm of occipital lobe
1915	Malignant neoplasm of ventricles

1916	Malignant neoplasm of cerebellum nos
1910	Malignant neoplasm of brain stem
1918	Malignant neoplasm of other parts of brain
1910	Malignant neoplasm of brain, unspecified
1919	Malignant neoplasm of other and ill-defined sites
1951	Malignant neoplasm of thorax
1952	Malignant neoplasm of abdomen
1953	Malignant neoplasm of pelvis
1958	Malignant neoplasm of other specified sites
1973	Secondary malignant neoplasm of other respiratory organs
1973 1974	Secondary malignant neoplasm of small intestine including duodenum
1974	Secondary malignant neoplasm of large intestine and rectum
1976	Secondary malignant neoplasm of retroperitoneum and peritoneum
1970 1977	Malignant neoplasm of liver, secondary
1977	Secondary malignant neoplasm of other digestive organs and spleen
1980	Secondary malignant neoplasm of kidney
1981	Secondary malignant neoplasm of other urinary organs
1982	Secondary malignant neoplasm of skin
1983	Secondary malignant neoplasm of brain and spinal cord
1984	Secondary malignant neoplasm of other parts of nervous system
1985	Secondary malignant neoplasm of bone and bone marrow
1986	Secondary malignant neoplasm of ovary
1987	Secondary malignant neoplasm of adrenal gland
1988	Other specified sites
19881	Secondary malignant neoplasm of breast
19882	Secondary malignant neoplasm of genital organs
19889	Secondary malignant neoplasm of other specified sites
1990	Disseminated malignant neoplasm without specification of site
1991	Other malignant neoplasm without specification of site
1992	Malignant neoplasm associated with transplant organ
20500	Acute myeloid leukemia, without mention of having achieved remission
20502	Acute myeloid leukemia, in relapse
20502	Subacute myeloid leukemia, without mention of having achieved remission
20520	Subacute myeloid leukemia, in relapse
20522	Myeloid sarcoma, without mention of having achieved remission
20530	Myeloid sarcoma, in relapse
20332	איזיבוטוע אמרכטווומ, ווו דבומטאב

20580	Other myeloid leukemia, without mention of having achieved remission
20582	Other myeloid leukemia, in relapse
20590	Unspecified myeloid leukemia, without mention of having achieved remission
20592	Unspecified myeloid leukemia, in relapse
20780	Other specified leukemia, without mention of having achieved remission
20800	Acute leukemia of unspecified cell type, without mention of having achieved remission
20880	Other leukemia of unspecified cell type, without mention of having achieved remission
20890	Unspecified leukemia, without mention of having achieved remission
20892	Unspecified leukemia, in relapse
2375	Neoplasm of uncertain behavior of brain and spinal cord
23873	High grade myelodysplastic syndrome lesions
2391	Neoplasm of unspecified nature of respiratory system
2396	Neoplasm of unspecified nature of brain
78951	Malignant ascites
Supplement	al Table E2: Previously published ICD-9-CM codes associated with a life-limiting
1.	

Supplemental Table E2: Previously published ICD-9-CM codes associated with a life-limiting malignancy converted to corresponding ICD-10-CM codes based on the CMS General Equivalency Mappings.


ICD-10	
Code	Diagnosis
C153	Malignant neoplasm of upper third of esophagus
C154	Malignant neoplasm of middle third of esophagus
C155	Malignant neoplasm of lower third of esophagus
C153	Malignant neoplasm of upper third of esophagus
C154	Malignant neoplasm of middle third of esophagus
C155	Malignant neoplasm of lower third of esophagus
C158	Malignant neoplasm of overlapping sites of esophagus
C159	Malignant neoplasm of esophagus, unspecified
C160	Malignant neoplasm of cardia
C164	Malignant neoplasm of pylorus
C163	Malignant neoplasm of pyloric antrum
C161	Malignant neoplasm of fundus of stomach
C162	Malignant neoplasm of body of stomach
C165	Malignant neoplasm of lesser curvature of stomach, unspecified
C166	Malignant neoplasm of greater curvature of stomach, unspecified
C168	Malignant neoplasm of overlapping sites of stomach

C169	Malignant neoplasm of stomach, unspecified
C220	Liver cell carcinoma
C222	Hepatoblastoma
C227	Other specified carcinomas of liver
C228	Malignant neoplasm of liver, primary, unspecified as to type
C221	Intrahepatic bile duct carcinoma
C229	Malignant neoplasm of liver, not specified as primary or secondary
C250	Malignant neoplasm of head of pancreas
C251	Malignant neoplasm of body of pancreas
C252	Malignant neoplasm of tail of pancreas
C253	Malignant neoplasm of pancreatic duct
C254	Malignant neoplasm of endocrine pancreas
C257	Malignant neoplasm of other parts of pancreas
C258	Malignant neoplasm of overlapping sites of pancreas
C259	Malignant neoplasm of pancreas, unspecified
C480	Malignant neoplasm of retroperitoneum
C481	Malignant neoplasm of specified parts of peritoneum
C488	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C482	Malignant neoplasm of peritoneum, unspecified
C260	Malignant neoplasm of intestinal tract, part unspecified
C261	Malignant neoplasm of spleen
C269	Malignant neoplasm of ill-defined sites within the digestive system
C269	Malignant neoplasm of ill-defined sites within the digestive system
C33	Malignant neoplasm of trachea
C3400	Malignant neoplasm of unspecified main bronchus
C3410	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C342	Malignant neoplasm of middle lobe, bronchus or lung
C3430	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C3480	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C3490	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C384	Malignant neoplasm of pleura
C380	Malignant neoplasm of heart
C381	Malignant neoplasm of anterior mediastinum

C382	Malignant neoplasm of posterior mediastinum
C388	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
C383	Malignant neoplasm of mediastinum, part unspecified
C390	Malignant neoplasm of upper respiratory tract, part unspecified
C399	Malignant neoplasm of lower respiratory tract, part unspecified
C399	Malignant neoplasm of lower respiratory tract, part unspecified
C710	Malignant neoplasm of cerebrum, except lobes and ventricles
C711	Malignant neoplasm of frontal lobe
C712	Malignant neoplasm of temporal lobe
C713	Malignant neoplasm of parietal lobe
C714	Malignant neoplasm of occipital lobe
C715	Malignant neoplasm of cerebral ventricle
C716	Malignant neoplasm of cerebellum
C717	Malignant neoplasm of brain stem
C718	Malignant neoplasm of overlapping sites of brain
C719	Malignant neoplasm of brain, unspecified
C761	Malignant neoplasm of thorax
C762	Malignant neoplasm of abdomen
C763	Malignant neoplasm of pelvis
C768	Malignant neoplasm of other specified ill-defined sites
C7839	Secondary malignant neoplasm of other respiratory organs
C784	Secondary malignant neoplasm of small intestine
C785	Secondary malignant neoplasm of large intestine and rectum
C786	Secondary malignant neoplasm of retroperitoneum and peritoneum
C787	Secondary malignant neoplasm of liver and intrahepatic bile duct
C787	Secondary malignant neoplasm of liver and intrahepatic bile duct
C7889	Secondary malignant neoplasm of other digestive organs
C7900	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C7911	Secondary malignant neoplasm of bladder
C7919	Secondary malignant neoplasm of other urinary organs
C792	Secondary malignant neoplasm of skin
C7931	Secondary malignant neoplasm of brain
C7932	Secondary malignant neoplasm of cerebral meninges
C7949	Secondary malignant neoplasm of other parts of nervous system
C7951	Secondary malignant neoplasm of bone
C7952	Secondary malignant neoplasm of bone marrow

C7960	Secondary malignant neoplasm of unspecified ovary
C7970	Secondary malignant neoplasm of unspecified adrenal gland
C7981	Secondary malignant neoplasm of breast
C7982	Secondary malignant neoplasm of genital organs
C7989	Secondary malignant neoplasm of other specified sites
C800	Disseminated malignant neoplasm, unspecified
C801	Malignant (primary) neoplasm, unspecified
C802	Malignant neoplasm associated with transplanted organ
C9200	Acute myeloblastic leukemia, not having achieved remission
C9240	Acute promyelocytic leukemia, not having achieved remission
C9250	Acute myelomonocytic leukemia, not having achieved remission
C9202	Acute myeloblastic leukemia, in relapse
C9242	Acute promyelocytic leukemia, in relapse
C9252	Acute myelomonocytic leukemia, in relapse
C9220	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission
C9222	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse
C9230	Myeloid sarcoma, not having achieved remission
C9232	Myeloid sarcoma, in relapse
C92Z0	Other myeloid leukemia not having achieved remission
C92Z2	Other myeloid leukemia, in relapse
C9290	Myeloid leukemia, unspecified, not having achieved remission
C9292	Myeloid leukemia, unspecified in relapse
C9430	Mast cell leukemia not having achieved remission
C9480	Other specified leukemias not having achieved remission
C9500	Acute leukemia of unspecified cell type not having achieved remission
C9590	Leukemia, unspecified not having achieved remission
C9590	Leukemia, unspecified not having achieved remission
C9592	Leukemia, unspecified, in relapse
D432	Neoplasm of uncertain behavior of brain, unspecified
D434	Neoplasm of uncertain behavior of spinal cord
D4622	Refractory anemia with excess of blasts 2
D491	Neoplasm of unspecified behavior of respiratory system
D496	Neoplasm of unspecified behavior of brain
R180	Malignant ascites

Additional Results



Association with ICU Beds

Figure E1: Correlation between available ICU beds and potentially preventable hospitalizations requiring ICU care across states.

The following figures E2 and E3 are presented as a visual check that the bootstrapped distributions of the differences in correlations were roughly normally distributed.




Figure E2: A bootstrapped estimate of the difference between correlation between ICU beds and all ICU admissions, and between ICU beds and ICU admissions associated with ACSC was calculated with 10,000 replicates. The distribution of differences between these values was mean-normalized across each year.




Figure E3: A bootstrapped estimate of the difference between correlations between ICU beds and all ICU admissions, and between ICU beds and ICU admissions associated with LLMs was calculated with 10,000 replicates. The distribution of differences between these values was mean-normalized across each year.

State comparisons

We calculated geographic differences at the state level (including Washington, DC, and Puerto Rico) in the MedPAR database. For between-state comparisons, we adjusted admission rates based on 2010 US Census data for each states' population distribution of age and gender (4). We identified the quintile of states with the lowest proportion of ICU admissions associated with each potentially preventable diagnosis. The following figures E4 and E5 demonstrate the state-level heterogeneity in admission rates, and use the lowest-admitting states to provide a conservative reference point for what a hypothetical floor on such a value might look like.

We observed a two-fold variation among states in potentially preventable ICU admissions in the FFS population (XXX). Among hospitalizations with ICU care, the average proportion with an ACSC ranged from 9.2% (95% CI 8.9 - 9.6) in North Dakota to 21.4% (95% CI 21.0 - 21.8) in Puerto Rico. The average proportion of hospitalizations with ICU care associated with a LLM ranged from 3.9% (95% CI 3.7 - 4.1) in Puerto Rico to 7.6% (95% CI 7.3 - 7.9) in Delaware.

Among hospitalizations associated with an ICU admission in the lowest quintile of states by ICU admission rates in the FFS population, 11.8% were for ACSCs (Supplemental Figure E4)

and 5.0% for LLMs (Supplemental Figure E5). If these estimates represented a lowerbound on achievable admission rates, we would still have observed 59,024 and 19,581 average yearly preventable hospital admissions with ICU care in the remaining states for ACSCs and LLMs, respectively.




Figure E4: Variation in the percentage of intensive care unit (ICU)-associated hospitalizations with administrative codes for ambulatory care sensitive conditions (ACSCs). Green dotted line indicates the mean admission rate among the lowest-admitting quintile of states.




Figure E5: Variation in the percentage of intensive care unit (ICU)-associated hospitalizations with administrative codes for life-limiting malignancies (LLMs). Green dotted line indicates the mean admission rate among the lowest-admitting quintile of states.




Figure E6: State-level differences in rates of intensive care unit (ICU) admissions for a potentially preventable cause among Medicare Fee-for-Service beneficiaries at least 65 years old adjusted for the age and gender distribution in each state (left panel), and as an unadjusted percentage of all ICU admissions (right panel). The y-axis shows admissions for life-limiting malignancies (LLMs) and the x-axis shows those for ambulatory care sensitive conditions (ACSCs). Correlations represent averages over the ten-year study period. Notably, state populations change relatively little while available ICU beds for admissions change rapidly and heterogeneously across states.

Sensitivity analysis





Figure E7: Sensitivity analysis results. Comparison of the observed and projected admission types in the fourth quarter of 2015. While observed and projected admissions differed substantially, the overall ten-year trends when calculated using the projected rates did not meaningfully differ.



Admissions by age among those with private insurance

Figure E8: Among those with private insurance, the proportion of potentially preventable hospitalizations by age, stratfied by whether or not the hospitalization was associated with an intensive care unit (ICU) stay. Notably, the privately insured cohort includes patients from newborns through age 65, in addition to those over 65.

References

1. Weissman GE, Hubbard RA, Kohn R, Anesi GL, Manaker S, Kerlin MP, Halpern SD. Validation of an administrative definition of intensive care unit admission using revenue center codes. *Crit Care Med* 2017;45:e758–e762.

2. Workgroup PQICM. Guide to Prevention Quality Indicators: Hospital Admission for Ambulatory Care Sensitive Conditions. 2014;

3. Obermeyer Z, Powers BW, Makar M, Keating NL, Cutler DM. Physician characteristics strongly predict patient enrollment in hospice. *Health Affairs* 2015;34:993–1000.

4. US Census Bureau PD. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States, States, Counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2014. 2015;